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EDITORIAL
How best to express oestrogen receptor activity
RA Hawkins
University Department of Surgery, Royal Infirmary ofEdinburgh Trust, Lauriston Place, Edinburgh EH3 9YW, UK.
The oestrogen receptor (ER), discovered around 1960
(Glascock and Hoekstra, 1959; Jensen and Jacobsen, 1960),
is present in the majority of breast cancers (70- 100%,
depending on method). Biochemical measurements of ER
activity have long been known to be of value for predicting
the outcome of endocrine therapy (NIH Consensus Meeting
1974, reported by McGuire et al., 1975) and also as a guide
to prognosis (Walt et al., 1976; Knight et al., 1977). Since
1980, however, the use and acceptance of receptor assays in
the management of breast cancer has had a chequered history
for a variety of reasons, including: poor quality control of
biochemical assays; poor control of specimen quality; changes
in methodology; use of receptor measurements as a
discontinuous variable (Altman, 1991; Simon and Altman,
1994) with an arbitrary 'cut-off' to decide receptor 'positivity/
negativity'; the advent of the relatively non-toxic endocrine
agent, tamoxifen; initial reports that benefit from adjuvant
therapy with tamoxifen was unrelated to receptor activity
(Novaldex Adjuvant Trial Organisation, 1983), although
subsequent reports have disagreed (Rose et al., 1985;
Scottish Breast Trials Committee, 1987; De Placido et al.,
1990; Early Breast Cancer Trialists, 1992); the need for an
adequate tumour specimen (50-250 mg); the advent of the
Breast Cancer Screening Program (Forrest, 1986), which
yields many impalpable tumours too small for biochemical
assay; the widely quoted view that '8- 10%' 'receptor-
negative' tumours respond to endocrine therapy-likely to be
untrue for the reasons discussed by, for example, Wittliffe,
(1988), and Robertson, (1996); the misconception that
tumour grade provides exactly the same information as
oestrogen receptor measurements, but at a lesser cost.
Despite these difficulties, today in 1996, ER measurements
are still recognised as being of importance for the manage-
ment of breast cancer, and the advent (King et al., 1985) of
immunohistochemical staining assays (IHAs) has afforded the
opportunity for considerable improvements in the provision
of receptor information as detailed below.
Now all tumours, irrespective of size, can be assayed - if
need be retrospectively - on paraffin blocks.
The contribution to receptor assay measurements by
contaminating benign tissue can be avoided.
The cost is lower (biochemical measurements are approxi-
mately £50 per specimen, IHA approx £3 10).
There is one problem, however, with the newer IHAs:
quantitation of receptor activity is more difficult. Over the
years, several studies have shown that receptor activity is a
continuous variable and increasing quantity of receptor is
associated with increasing probability of response/better
prognosis (eg. Leclercq and Heuson, 1976, 1977; McGuire
et al., 1978; Campbell et al., 1981; Shek and Godolphin,
1989).
In the present issue, Dr Diana Barnes and her colleagues
thus address an issue of some importance. In this study, Dr
Barnes' group has examined the relative merits of six different
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modes ofexpressing the results of IHA for ER in the paraffin
sections from 170 patients treated with tamoxifen for
metastatic breast cancer. The IHA results are assessed in
relation to both clinical outcome and the results of a
biochemical (ligand-binding) assay, carried out some 17
years previously. The patients studied were a selected, mixed
group of 133 with operable primary disease, 23 with locally
advanced disease and 14 with distant metastases at
presentation, but overall showed a 51% rate of response.
In gauging the relative merits of the various modes of
assessing IHA and the results of the biochemical assay, the
ICRF group has expressed 'receptor status' by dividing the
scores or values according to fixed criteria, usually defined
previously by the originator of the mode examined. Thus
'receptor status' is expressed in a number of categories: two
(biochemical assay, 'histo score'), three ('quick score') or four
('category score'). The key finding of the study is that, in
general, all the modes for expressing IHA results were
significantly related to outcome on endocrine therapy, with
the 'quick score' of marginally greater significance. The
biochemical ER assay, too, was significantly related to
outcome but, as the authors note, it is unfair to draw
conclusions concerning the comparison of such assays
performed 17 years previously by the older ligand-binding
assay (compare the more quantitative ER-EIA or enzyme
immunoassay) with immunocytochemical assays in a non-
prospective study.
ER expression is a continuous variable, with concentra-
tions scattered over a large spectrum (Leclercq and Heuson,
1976, 1977). In Dr Barnes' paper, and in the real world,
where IHAs now prevail for the reasons discussed above, it is
probably necessary to down-grade the continuum into
categories, for convenience. Nevertheless, the ER expressed
as a continuum is the most prognostic/predictive form of the
variable, measuring the probability of the tumour's biological
behaviour. For this reason, modes ofexpressing ER results in
only two categories are less informative and less predictive
than those dividing into three or four categories, and the x2
values and significances for the relationship between 'ER' and
time to progression increase with increasing number of
categories into which the 'ER-IHA' score is divided. In the
light of this, it would seem imprudent to return to Jensen's
original proposal of a two-category system, ie. 'ER-positive'
and 'ER-negative', using an arbitrary cut-off. I believe that it
is perfectly possible for the results of IHAs to be divided into
a minimum of four categories ('negative', 'low', 'medium' and
'high') to yield prognostic/predictive information virtually
equivalent to that provided, as a continuum, by a sensitive,
quantitative biochemical assay such as the ER-EIA.
For the present, Dr Barnes and her colleagues have clearly
demonstrated the value of ER-IHAs for predicting response
to endocrine therapy and that all the modes of expressing the
IHA score studied were of value. Whether the optimal mode
of assessing IHAs has yet been reached remains to be seen.
As ER concentrations are logarithmically distributed and the
probability of response is sigmoidally related to the log of ER
concentration (Leclercq and Heuson, 1976, 1977), it might be,
for example, that division of IHA into four categories of
doubling scores would prove more useful than the modesHow best to express ER activit
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examined to date. It seems likely that fine-tuning the mode of
assessment of IHAs will eventually lead to a single, definitive
method that can be the standard for all histopathology
laboratories. This, coupled with appropriate quality control,
should lead to provision ofa more accurate assessment of ER
expression within a breast cancer and hence of the tumour's
biological behaviour than has hitherto been generally
available to the clinical team who manage breast cancer.
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